Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon - Based 1 Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype - 1 b Hepatitis
نویسندگان
چکیده
27 Because of recent advances in deep sequencing technology, detailed analysis of 28 hepatitis C virus (HCV) quasispecies and its dynamic change in response to direct 29 antiviral agents (DAAs) became possible although the role of quasispecies is not fully 30 understood. In this study, to clarify the evolution of viral quasispecies and the origin of 31 drug-resistant mutations induced by interferon-based protease inhibitor therapy, the 32 nonstructural-3 (NS3) region of genotype 1b HCV in 34 chronic hepatitis patients 33 treated with telaprevir (TVR)/pegylated-interferon (PEG-IFN)/ribavirin (RBV) was 34 subjected to a deep sequencing study coupled with phylogenetic analysis. Twenty-six 35 patients (76.5%) achieved a sustained viral response (SVR) while 8 patients did not 36 (non-SVR, 23.5%). When the complexity of the quasispecies was expressed as mutation 37 frequency or Shannon entropy, a significant decrease in the IFNL3 (rs8099917) TT 38 group and a marginal decrease in the SVR group were found soon (12 h) after the 39 introduction of treatment, whereas there was no decrease in the non-SVR group and no 40 significant decrease in mutation frequency in the IFNL3 TG/GG group. In the analysis 41 of viral quasispecies composition in non-SVR patients, major populations greatly 42 changed accompanied by the appearance of resistance and the compositions were 43 unlikely to return to the pretreatment composition even after the end of therapy. 44 Clinically TVR-resistant variants were observed in 5 non-SVR patients (5/8, 62.5%), all 45 of which were suspected to have acquired resistance by mutations through phylogenetic 46 analysis. In conclusion, results of the study have important implications for treatment 47 response and outcome in interferon-based protease inhibitor therapy. 48 49 IMPORTANCE 50 In the host, hepatitis C virus (HCV) consists of a variety of populations 51 on July 4, 2017 by gest http/jvi.asm .rg/ D ow nladed fom
منابع مشابه
Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.
In the TMC435-C101 study, 6 patients infected with hepatitis C virus genotype 1 were treated with the protease inhibitor TMC435 (200 mg once daily) as monotherapy for 5 days. Approximately 1.5 years later, 5 of these patients were re-treated with TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week...
متن کاملIdentification of Drug Resistant Mutants of HBV (Hepatitis B Virus) by Direct Sequencing in Iranian Patients Treated with Lamivudine
Background and Aims: lamivudine is amongst the antiviral for drug chronic hepatitis B treatment. During therapy with lamivudine, variants may emerge with YMDD mutation in the reverse transcriptase (RT) region of polymerase gene. This mutation might have a role in drug resistant for HBV. Materials and Methods: HBV DNA extraction from serum sample of 88 patients, were subjected to nested PCR for ...
متن کاملMK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections. Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes fo...
متن کاملNo correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
Direct-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C virus (HCV) infection. However, protease inhibitor (PI)-resistant viral variants have been often described. This study aimed to examine HCV-NS3 protease variants at baseline and at 4 weeks under triple therapy. To this end, we analyzed the presence of variants in HCV-NS3 protease region from periph...
متن کاملNationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations
BACKGROUND AND AIMS The first standard of care in treatment of chronic HCV genotype 1 infection involving directly acting antivirals was protease inhibitors telaprevir or boceprevir combined with pegylated-interferon and ribavirin (triple therapy). Phase III studies include highly selected patients. Thus, treatment response and development of viral resistance during triple therapy in a routine ...
متن کامل